Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer

  • Brandariz, Julian
  • De Llobet, Lara
  • Esquefa, Victor
  • Aguilar, Daniel
  • Salca, Andrei
  • Arce-Gallego, Sara
  • Cresta Morgado, Pablo
  • Sole, Arnau
  • Agundez, Laura
  • Mir, Gisela
  • Castro, Natalia
  • Casals, Teresa
  • Oliveira, Anna
  • Casanova-Salas, Irene
  • Malumbres, Marcos
  • Morella-Aucejo, Ángela|||0000-0002-6357-949X
  • Bernardos Bau, Andrea|||0000-0002-3842-5771
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Metastatic prostate cancer (mPC) is a lethal disease; most therapeutic options focus on androgen receptor signaling inhibition, but resistance eventually arises. Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) have shown antitumor efficacy in mPC preclinical models, but their efficacy in mPC clinical trials has been limited. We hypothesize that novel combination therapies designed leveraging mPC adaptation to CDK4/6i could lead to increased and sustained antitumor effect. In this study, we demonstrate in a range of in vitro and in vivo prostate cancer models, including patient-derived xenografts, that prostate cancer cells adopt a senescent phenotype upon CDK4/6 inhibition that can be selectively targeted using senolytic compounds. Notably, interrupting CDK4/6 inhibition in intermittent drug schedules prompts a rapid bypass of the senescent phenotype that is associated with a temporal downregulation of replisome proteins in Rb-proficient but not in Rb-deficient models, leading to DNA damage accumulation and replication stress following treatment withdrawal. This effect opens a window of opportunity for treatment with PARP inhibitors (PARPi): Although upfront combined inhibition of CDK4/6 and PARP1 had no antitumor effect, their sequential use adding PARPi upon CDK4/6i withdrawal and cell-cycle reentry results in major antitumor activity. Our findings underscore the potential of CDK4/6i in prostate cancer therapy, particularly when administered under biology-driven sequential use of senolytic therapy or PARPi. Such strategic interventions hold promise in overcoming resistance and enhancing treatment outcomes for patients with advanced prostate cancer and open avenues for repurposing CDK4/6i therapy in mPC., This work was funded by Fundacion AECC (grants PRYCO211023SERR and LABAE20019MATE), Instituto de Salud Carlos III (PI20/0058) and Fundacion FERO. S. Arce-Gallego and N. Herranz were supported by Instituto de Salud Carlos III through fellowships FI19/00280 and CP19/00170, respectively. I. Casanova-Salas is supported by a Prostate Cancer Foundation Young Investigator Award (24YOU12). J. Mateo is supported by the CRIS Cancer Foundation (grant TCL-2020-10) and a DoD Congressionally Directed Medical Research Programs Physician Science Award (PC220307). Vall d'Hebron Institute of Oncology authors would like to thank the Spanish State Agency for Research (Agencia Estatal de Investigacion) for the financial support under Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment, and the CERCA Program from the Generalitat de Catalunya for their support on this research. We would like to thank the Vall d'Hebron Institute of Oncology High Technology Unit, especially Dr. Elena Serrano Carballal, for their assistance in designing and analyzing the imaging experiments. We also extend our thanks to Guadalupe Espadas-Garcia for conducting the proteomic analyses at the Centre de regulacio genomica/Universitat Pompeu Fabra Proteomics Unit, which is part of the Spanish National Infrastructure for Omics Technologies (ICTS Omicstech). Lastly, we would like to thank Paula Garcia Carrascosa for creating the illustrations featured in the manuscript figures.